The estimated Net Worth of Manu Chakravarthy is at least $1.98 Milión dollars as of 1 February 2021. Mr. Chakravarthy owns over 60,000 units of Axcella Health Inc stock worth over $274,800 and over the last 5 years he sold AXLA stock worth over $0. In addition, he makes $1,709,890 as Senior Vice President a Chief Medical Officer at Axcella Health Inc.
Manu has made over 1 trades of the Axcella Health Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of AXLA stock worth $274,800 on 1 February 2021.
The largest trade he's ever made was exercising 60,000 units of Axcella Health Inc stock on 1 February 2021 worth over $274,800. On average, Manu trades about 15,000 units every 0 days since 2019. As of 1 February 2021 he still owns at least 60,000 units of Axcella Health Inc stock.
You can see the complete history of Mr. Chakravarthy stock trades at the bottom of the page.
Manu V. Chakravarthy serves as Senior Vice President, Chief Medical Officer of the Company., Ph.D. is Senior Vice President of Clinical Development, Chief Medical Officer of Company.Dr. Chakravarthy served as the Global Head of External R&D in diabetes and cardiovascular research at Eli Lilly & Co where he was responsible for external innovation efforts, including the identification/evaluation of novel therapeutics, platforms, and technologies for in/out-licensing, establishing academic collaborations, and consortia management across the value chain to complement and enhance Lilly’s internal R&D portfolio. He also served as the industry co-leader of the Innovative Medicine Initiative’s LITMUS project, one of the largest public-private consortia efforts to elucidate noninvasive biomarkers for NAFLD. Before his global leadership role at Lilly, Dr. Chakravarthy spent more than 7 years at Merck & Co., where he began his industry career in Experimental Medicine as an associate director and progressively gained increasing experience across the R&D spectrum from discovery, clinical pharmacology, biomarker development and late-stage drug development in endocrine, metabolic, neuroscience and anti-viral therapeutic areas. During this time, he assumed positions of increasing responsibility and leadership within the company, ultimately serving as a Distinguished Scientist and led the clinical pharmacology groups in Discovery Medicine for groups in diabetes and cardiometabolic diseases within Translational Medicine. Dr. Chakravarthy received his medical degree from the University of Texas Houston Medical School, his doctorate in cell biology & physiology from the University of Texas Graduate School of Biomedical Sciences and the MD Anderson Cancer Center, and his bachelor’s degree in Liberal Arts from St. John’s University. He completed a residency in Internal Medicine at the Hospital of the University of Pennsylvania and clinical Fellowship in Endocrinology, Diabetes & Metabolism at the Barnes-Jewish Hospital in St Lou
As the Senior Vice President a Chief Medical Officer of Axcella Health Inc, the total compensation of Manu Chakravarthy at Axcella Health Inc is $1,709,890. There are 1 executives at Axcella Health Inc getting paid more, with Shreeram Aradhye having the highest compensation of $3,911,720.
Manu Chakravarthy is 46, he's been the Senior Vice President a Chief Medical Officer of Axcella Health Inc since 2017. There are 15 older and 2 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
Manu's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... a Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Axcella Health Inc executives and other stock owners filed with the SEC include: